StayHappi is planning to start this initiative in 10 states in the first quarter, starting with Delhi.
With the purpose to serve humanity by providing High-Quality Medicines at ‘Real and Affordable’ price, Self-funded medicine start-up StayHappi has announced its entry into the Indian market.
StayHappi was incepted in October 2017 and after R&D has rolled out its first pharmacy in Rani Bagh, New Delhi.
The company provides medicines with their molecule name and not by the brand name, where patients will have the power to choose the right medicine and make a smart choice. The main objective of the company is primarily to serve the People of the country with affordable, quality generic medicines and is committed to expanding its reach to each and every citizen of India.
StayHappi is planning to start this initiative in 10 states in the first quarter, starting with Delhi and will gradually have more pharmacy stores in cities including Mumbai, Bangalore, Chennai, Hyderabad, Kolkata, Ahmedabad, Lucknow, Bhopal, Patna, and Bhuwaneshwar. Each state will have a substantial number of stores to cater to the demand.
Dr. Sujit Paul, Managing Director, StayHappi, said, “It gives us immense pleasure to announce our footings into the retail pharmacy industry in India. Before starting our journey, we did a lot of research and development to understand the market challenges and the medicines available to the patients. Our aim is to provide medicines with their molecule name and not by the brand name at an.”
“Health is very important and choosing the right medicines is the patient’s right to make better choices. If a person is in the pink of health, he finds the strength to do any work, relishes the food and can go through life’s journey with joy. A good health is a priceless blessing and keeping that in mind, we formed StayHappi to make the “Health for all” a reality,” he went on saying.
StayHappi has also planned to scale up to 15,000 retail pharmacy stores across the country within three year’s time. It will also launch 1,000 products in a phased manner and will further add products that would offer a comprehensive range of products covering all types of therapeutic form, dosage forms, consumables and healthcare products.